Driven by large language models, AI agents are transforming drug discovery, enabling AI to break free from task-specific tools and advance toward the vision of autonomous virtual scientists. This perspective reviews applications across the R&D lifecycle. To evaluate system maturity, we introduce a 6-level “Spectrum of Agentic Autonomy.” We advocate for novel evaluation paradigms centered on full-chain traceability and outline adoption barriers, positioning AI agents as pragmatic scientist-in-the-loop co-pilots.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: